Colin Kellaher, The Wall Street Journal Journalist Profile

Articles

FactSet CEO Snow to Retire; JPMorgan's Viswanathan to Take Helm

3 days ago | tradingview.com | Colin Kellaher

FactSet CEO Snow to Retire; JPMorgan's Viswanathan to Take HelmFDSFactSet Research Systems' chief executive, Phil Snow, is retiring after a decade at the helm, and the financial-data provider has hired JPMorgan Chase veteran Sanoke Viswanathan to succeed him. FactSet on Tuesday said Viswanathan, who has been chief executive of JPMorgan's international consumer and wealth arm and a member of the bank's operating committee since June 2024, will join the Norwalk, Conn., company in early September.
Circle Internet Group Boosts Size, Price Range of IPO

4 days ago | tradingview.com | Colin Kellaher

Circle Internet Group Boosts Size, Price Range of IPOCircle Internet Group could fetch an initial market capitalization topping $6.3 billion after the stablecoin issuer boosted the size and price range of its planned initial public offering. Circle, the issuer of the crypto stablecoin USDC, on Monday said it now plans to sell 12.8 million shares at between $27 and $28 apiece in the IPO, up from prior plans to offer 9.6 million shares at $24 to $26 each.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

4 days ago | wsj.com | Colin Kellaher

Deal potentially worth more than $11 BillionBioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker. Shares of BioNTech, which closed Friday at $95.81, rose 14% to $109.54 in premarket trading Monday. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4 days ago | tradingview.com | Colin Kellaher

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 BillionBNTXBMYBioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker. Shares of BioNTech, which closed Friday at $95.81, rose 14% to $109.54 in premarket trading Monday.
Theravance Shares Rise Premarket on Sale of Trelegy Royalties

4 days ago | tradingview.com | Colin Kellaher

Theravance Shares Rise Premarket on Sale of Trelegy RoyaltiesTheravance Biopharma shares rose sharply in premarket trading Monday after the biopharmaceutical company said it agreed to sell its remaining royalty interest in sales of the lung-disease treatment Trelegy Ellipta to U.K. drugmaker GSK for $225 million in cash. Shares of Theravance, which closed Friday at $9.16, were recently up 9.3% to $10.01 in premarket trading.
EchoStar Shares Fall on Skipped Note Interest Payment

1 week ago | morningstar.com | Colin Kellaher

By Colin Kellaher EchoStar shares fell sharply on Friday after the network operator skipped a $326 million cash interest payment due on some of its notes amid a U.S. regulatory review of its use of cellular and satellite spectrum licenses. EchoStar shares were recently changing hands at $17.75, down 12%.
Boston Scientific Ending Acurate Sales, Approval Efforts

1 week ago | tradingview.com | Colin Kellaher

Boston Scientific Ending Acurate Sales, Approval EffortsBSXBoston Scientific is throwing in the towel on its Acurate transcatheter aortic valve replacement, or TAVR, platform, citing rising costs of efforts to win regulatory approvals. Boston Scientific on Wednesday said it is ending worldwide sales of its Acurate neo2 and Prime aortic valve systems, and that it is no longer pursuing regulatory approvals for Acurate in the U.S. or other geographies.
USDC Stablecoin Issuer Circle Sets IPO Terms That Could Push Market Cap Above $5.7 Billion

1 week ago | uk.marketscreener.com | Colin Kellaher

Published on 27/05/2025 at 13:39 By Colin Kellaher Circle Internet Group unveiled terms of a planned initial public offering that could give the stablecoin issuer a market capitalization topping $5.7 billion. Circle on Tuesday said it plans to sell 9.6 million shares at between $24 and $26 apiece in the IPO.
Visa Europe CEO Charlotte Hogg Leaving for Fund Servicer Alter Domus

1 week ago | morningstar.com | Colin Kellaher

By Colin Kellaher Charlotte Hogg, the former Bank of England executive who has been at the helm of Visa's European operations since late 2017, is leaving the credit-card giant to become chief executive of private-equity backed fund-services provider Alter Domus. Visa on Tuesday said Antony Cahill, who has been president of its value-added services business since 2023, will succeed Hogg as CEO of its European operations early next month.
Kansas City Fed Services Activity Index Rises in May

2 weeks ago | tradingview.com | Colin Kellaher

Kansas City Fed Services Activity Index Rises in MayServices activity in the middle of the U.S. grew in May, and expectations for future activity remained positive, according to a monthly survey by the Federal Reserve Bank of Kansas City released Friday. The Tenth District Services Survey's composite index, a weighted average of indexes covering revenue/sales, employment and inventory, came in at 11 in May, up from 3 in April and 0 in March.